About Dimension
Dimension is a venture capital firm founded in 2019. It is primarily based out of New York City, United States. As of Aug 2026, Dimension is an active investor, having invested in 17 companies, with 4 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series B round of Lanyon AI Overall, Dimension portfolio has seen 3 unicorns, 1 IPO and 1 acquisition including key companies like Chai Discovery, Odyssey and Enveda. A lot of funds co-invest with Dimension, with names like DST Global sharing a substantial percentage of its portfolio. Dimension has team of 6 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Seed & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
Dimension's List of Top Investments
Dimension has a portfolio of 17 companies, including 3 unicorns. Their most notable investments are in Automata and Automata.Their portfolio spans across United States, Canada and United Kingdom. They have invested in Life Sciences, Enterprise Applications, High Tech and 4 other sectors, across stages such as Series B, Seed and 2 more. Here is the list of top investments by Dimension:Developer of artificial intelligence models for de novo molecular design. The company focuses on engineering better molecules through advanced computational methods. It introduces new model series designed to achieve high hit rates in antibody design. The company provides access to its technology for molecular research and development.
Key facts about Chai Discovery
- Founded Year: 2023
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $630M
- Investors: Sapphire Ventures, Baillie Gifford and 28 Others
- Latest Funding Round: Series C, Jul 14, 2026, $*****
- Highlight: Editors' Pick
Developer of bioprinting technology and tissue therapeutics for regenerative medicine. The company’s platform integrates bioprinting, computational design, therapeutic cells, and biomaterials. It develops implantable tissues to replace, repair, or supplement biological functions. The focus is on creating solutions for metabolic and endocrine diseases. The company also collaborates with other organizations.
Key facts about Aspect Biosystems
- Founded Year: 2013
- Location: Vancouver (Canada)
- Stage: Series B
- Total Funding till date: $139M
- Employee Count: 143 as on Jul 31, 2026
- Investors: Rising Tide Fund, Pangaea Ventures and 21 Others
- Latest Funding Round: Series B, Jan 08, 2025, $*****
- Highlight: Editors' Pick
3. Automata
Developer of modular lab automation platforms for biological research workflows. This system integrates hardware and software to orchestrate laboratory processes, including sample handling and instrument management. The platform utilizes node-based design tools and software development kits to enable workflow configuration and simulation. It supports connectivity with external data systems and analytical models to facilitate automated execution of experimental protocols. The hardware components are configurable to accommodate various instruments and laboratory layouts, allowing for the management of multiple concurrent tasks.
Key facts about Automata
- Founded Year: 2015
- Location: London (United Kingdom)
- Annual Revenue: £1M - £10M as on Mar 31, 2025
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $177M
- Employee Count: 165 as on Jul 31, 2026
- Investors: Isomer Capital, Hummingbird Ventures and 26 Others
- Latest Funding Round: Series C, Jan 29, 2026, $*****
- Highlight: Editors' Pick
4. Odyssey
Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.
Key facts about Odyssey
- Founded Year: 2018
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $717M
- Employee Count: 123 as on Jul 31, 2026
- Investors: Colt Ventures, T. Rowe Price and 29 Others
- Latest Funding Round: Series D, Jun 16, 2025, $*****
- Highlight: Public
5. Enveda
AI-based platform to decipher the chemistry of nature and develop new medicines. It employs advanced computational methods, high throughput automation, and metabolomics to identify potential treatments for various diseases. It leverages chemical knowledge of nature to accelerate drug discovery and development.
Key facts about Enveda
- Founded Year: 2019
- Location: Boulder (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $517M
- Employee Count: 153 as on Aug 31, 2025
- Investors: Allen & Company, Baillie Gifford and 30 Others
- Latest Funding Round: Series D, Sep 04, 2025, $*****
- Highlight: Editors' Pick
Dimension's Year-on-Year Investment Trends
Dimension has invested in 17 companies over the last 4 years, with an average of 4 new investments annually in the last 3 years. In 2025, it made 11 investments, while as of Aug 2026, it has made 5 investments in this year. Its most recent first time investment was in Lanyon AI and most recent follow-on round was in Chai Discovery.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 2 | 5 |
2025 | 9 | 2 | 11 |
2024 | 0 | 1 | 1 |
2023 | 1 | 1 | 2 |
2022 | 2 | 0 | 2 |
Dimension's Investments by Stage
Dimension has made 7 investments in Series B stage with an average round size of $46.2M, 4 investments in Seed stage with an average round size of $10.4M, 2 investments in Series A stage with an average round size of $41.8M and 2 investments in Series D stage with an average round size of $501M.Stage of entry | No. of Investments |
|---|---|
Series B | 7 |
Seed | 4 |
Series A | 2 |
Series D | 2 |
Note: We have considered here, only first round of investments
Dimension's Investments by Sector
Dimension has a diverse portfolio, with companies operating in the Enterprise Applications, Life Sciences, HealthTech, High Tech and Artificial Intelligence - Industry Applications. Notably, it has invested in 16 Enterprise (B2B) companies, 16 Tech companies, 13 Software companies and at least 6 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Enterprise Applications | 12 |
Life Sciences | 12 |
HealthTech | 7 |
High Tech | 5 |
Artificial Intelligence - Industry Applications | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
Dimension's Investments by Geography
Dimension has made most investments in United States (11), followed by Canada where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 11 |
Canada | 2 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Dimension's recent investments
Dimension has made 5 investments in 2026 so far. Lanyon AI and Chai Discovery are the latest among them.Here are the most recent investments by Dimension:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 17, 2026 | - | Series B | 5434 | ||
Jul 14, 2026 | United States | Series C | 8052 | [+17] | |
Mar 23, 2026 | Canada | Series B | 7277 | [+7] | |
Mar 20, 2026 | United States | Series D | 5714 | [+5] | |
Jan 29, 2026 | United Kingdom | Series C | 2003 | [+3] |
Unicorns in Dimension's Portfolio
Dimension has 3 unicorns in its portfolio - Chai Discovery, NewLimit and Enveda. The most recent unicorn in their portfolio is Chai Discovery. It became a unicorn in 2025.Here is a list of unicorns in Dimension's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
69 | Developer of artificial intelligence models for de novo molecular design | 2023 | San Francisco | Series C | p{tqn{e | ||
63 | Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension | 2022 | San Francisco | Series C | niqsgwy | ||
63 | AI-based platform to decipher the chemistry of nature and develop new medicines | 2019 | Boulder | Series D | gtok{ve |
IPOs and Publicly Listed companies in Dimension's Portfolio
1 of Dimension's portfolio company became public - Odyssey. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2026 at marketcap of $849MHere are Dimension's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 08, 2026 | Jun 16, 2025 | Series D | 3806 |
Acquired companies in Dimension's Portfolio
1 company from Dimension's portfolio has been acquired. The most recent acquisition was Stealth BioTherapeutics in Aug 2022 by Morningside for $*****.Here are Dimension's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 01, 2022 | - | - | 2563 |
Team profile of Dimension
Dimension has a team of 6 members including 3 Partners located in United States. Dimension's team does not sit on the board of any company as of now.Here is a list of all team members in Dimension:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - |
Co-investors of Dimension
Over the past 4 years, 172 investors have co-invested in Dimension's portfolio companies. This includes funds and angels.
- Invested before Dimension: Hummingbird Ventures, Alexandria and 73 others have invested in rounds before Dimension. There are 2 companies where Hummingbird Ventures has invested before Dimension and 2 companies where Alexandria has invested before Dimension.
- Top Co-investors of Dimension: 65 investors entered a company along with Dimension. These include investors like DST Global (2 companies).
- Invested after Dimension: A total of 32 investors have invested in Dimension's portfolio after their investments. Top Investors include Baillie Gifford (2 companies), General Catalyst (1 company) and Oak HC/FT (1 company).
Recent News related to Dimension
•
•
Congruence Therapeutics Raises $39.5M in FundingFinSMEs•Mar 23, 2026•Congruence Therapeutics, Dimensions, Amplitude, Invest Quebec and 5 others
•
Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual ReportBusiness Wire•Mar 18, 2026•Sensorion, Sanofi, Dimension Capital Management, Pfizer and 7 others
•
US AI drug startup Earendil said to consider Hong Kong IPOTech in Asia•Mar 13, 2026•Earendil, Dimension, Luminous Ventures, DST Global
•
OpenAI-Backed Chai Discovery Lands $130M to Accelerate AI Molecule DesigneWEEK•Dec 15, 2025•Chai Discovery, OpenAI, Oak HC/FT, Thrive Capital and 8 others
•
Coinbase CEO’s Longevity Startup Raises $45M From Eli Lilly & OthersAthletech News•Oct 21, 2025•S32, Dimension, NewLimit, Human Capital and 4 others
•
Jeito Capital Invests in Odyssey Therapeutics' $213M Series D FundingGlobeNewswire•Sep 10, 2025•Jeito, Odyssey, Affinity Asset Advisors, Dimension Capital Management and 4 others
•
Portland startup Fiveonefour funding totals $17MSilicon Florist•Sep 04, 2025•Neoclassic Capital, fiveonefour, Dimension, Volt Capital and 4 others
•
•
Convoke Secures $8.6M to Develop AI Operating System for BiopharmaPR Newswire•Aug 19, 2025•Convoke, Dimension, Kleiner Perkins, Comma Capital and 5 others
